Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D Spending Projected To Decline in 2018 As Rebates Increase

Executive Summary

Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.

You may also be interested in...

Medicare Part D Spending in 2019 Lower Than Expected Because Of Rebates

Medicare Trustees Report highlights importance of rebates in Part D but does not address potential changes to system; charts detail the growing impact rebates are expected to have in coming years.

Medicare Part D Spending On Established Brands Grew 62% Despite Rebates

HHS Office of Inspector General traces reimbursement, pricing, rebating and utilization patterns for established brands from 2011 to 2015.

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

The reform 'blueprint' might actually live up to its hype.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts